| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US7285668 | TAKEDA PHARMS USA | Process for the crystallization of (R)- or (S)-lansoprazole |
Jun, 2020
(3 years ago) | |
| US6462058 | TAKEDA PHARMS USA | Benzimidazole compound crystal |
Jun, 2020
(3 years ago) | |
| US9145389 | TAKEDA PHARMS USA | Benzimidazole compound crystal |
Jun, 2020
(3 years ago) | |
| US6664276 | TAKEDA PHARMS USA | Benzimidazole compound crystal |
Jan, 2023
(1 year, 2 months ago) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US7399485 | TAKEDA PHARMS USA | Rapidly Disintegrable solid preparation |
May, 2018
(5 years ago) | |
|
US7399485 (Pediatric) | TAKEDA PHARMS USA | Rapidly Disintegrable solid preparation |
Nov, 2018
(5 years ago) | |
| US7875292 | TAKEDA PHARMS USA | Orally disintegrable tablets |
May, 2019
(4 years ago) | |
| US7431942 | TAKEDA PHARMS USA | Orally disintegrable tablets |
May, 2019
(4 years ago) | |
| US6328994 | TAKEDA PHARMS USA | Orally disintegrable tablets |
May, 2019
(4 years ago) | |
| US6238994 | TAKEDA PHARMS USA | Method of creating a rough electrode (high surface area) from Ti and TiN and resulting article |
May, 2019
(4 years ago) | |
|
US6238994 (Pediatric) | TAKEDA PHARMS USA | Method of creating a rough electrode (high surface area) from Ti and TiN and resulting article |
Nov, 2019
(4 years ago) | |
|
US7431942 (Pediatric) | TAKEDA PHARMS USA | Orally disintegrable tablets |
Nov, 2019
(4 years ago) | |
|
US7875292 (Pediatric) | TAKEDA PHARMS USA | Orally disintegrable tablets |
Nov, 2019
(4 years ago) | |
|
US6328994 (Pediatric) | TAKEDA PHARMS USA | Orally disintegrable tablets |
Nov, 2019
(4 years ago) | |
| US6939971 | TAKEDA PHARMS USA | Benzimidazole compound crystal |
Jun, 2020
(3 years ago) | |
|
US7285668 (Pediatric) | TAKEDA PHARMS USA | Process for the crystallization of (R)- or (S)-lansoprazole |
Dec, 2020
(3 years ago) | |
|
US6462058 (Pediatric) | TAKEDA PHARMS USA | Benzimidazole compound crystal |
Dec, 2020
(3 years ago) | |
|
US6939971 (Pediatric) | TAKEDA PHARMS USA | Benzimidazole compound crystal |
Dec, 2020
(3 years ago) | |
|
US6664276 (Pediatric) | TAKEDA PHARMS USA | Benzimidazole compound crystal |
Jul, 2023
(8 months ago) | |
| US8784885 | TAKEDA PHARMS USA | Controlled release preparation |
Oct, 2023
(6 months ago) | |
|
US8784885 (Pediatric) | TAKEDA PHARMS USA | Controlled release preparation |
Apr, 2024
(5 days ago) | |
| US8461187 | TAKEDA PHARMS USA | Multiple PPI dosage form |
Jan, 2026
(1 year, 8 months from now) | |
| US9238029 | TAKEDA PHARMS USA | Multiple PPI dosage form |
Jan, 2026
(1 year, 8 months from now) | |
| US9011926 | TAKEDA PHARMS USA | Method for producing granules |
Feb, 2026
(1 year, 10 months from now) | |
|
US8461187 (Pediatric) | TAKEDA PHARMS USA | Multiple PPI dosage form |
Jul, 2026
(2 years from now) | |
| US8871273 | TAKEDA PHARMS USA | Method for producing granules |
Jan, 2028
(3 years from now) | |
|
US8871273 (Pediatric) | TAKEDA PHARMS USA | Method for producing granules |
Jul, 2028
(4 years from now) | |
| US9241910 | TAKEDA PHARMS USA | Orally-disintegrating solid preparation |
Mar, 2029
(4 years from now) | |
Dexilant Solutab is owned by Takeda Pharms Usa.
Dexilant Solutab contains Dexlansoprazole.
Dexilant Solutab has a total of 28 drug patents out of which 21 drug patents have expired.
Expired drug patents of Dexilant Solutab are:
- US7399485
- US7399485*PED
- US7875292
- US7431942
- US6328994
- US6238994
- US6238994*PED
- US7431942*PED
- US7875292*PED
- US6328994*PED
- US6939971
- US7285668*PED
- US6462058*PED
- US6939971*PED
- US6664276*PED
- US8784885
- US8784885*PED
- US7285668
- US6462058
- US9145389
- US6664276
Dexilant Solutab was authorised for market use on 26 January, 2016.
Dexilant Solutab is available in tablet, orally disintegrating, delayed release;oral dosage forms.
Dexilant Solutab can be used as treatment of heartburn associated with non-erosive gastroesophageal reflux disease (gerd) for 4 weeks, maintain healing of erosive esophagitis (ee) for up to 6 months.
The generics of Dexilant Solutab are possible to be released after 10 March, 2029.
Drugs and Companies using DEXLANSOPRAZOLE ingredient
Market Authorisation Date: 26 January, 2016
Treatment: Treatment of heartburn associated with non-erosive gastroesophageal reflux disease (gerd) for 4 weeks; Maintain healing of erosive esophagitis (ee) for up to 6 months
Dosage: TABLET, ORALLY DISINTEGRATING, DELAYED RELEASE;ORAL
DEXILANT SOLUTAB family patents
